Chemical: Drug
sulfadiazine

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.


Annotated Labels

  1. FDA Label for sulfadiazine and G6PD
  2. HCSC Label for sulfadiazine and G6PD

last updated 09/01/2016

1. FDA Label for sulfadiazine and G6PD

Actionable PGx

Genes and/or phenotypes found in this label

  • Sepsis
    • Indications & usage section
    • source: U.S. Food and Drug Administration
  • G6PD
    • toxicity, Warnings section
    • source: U.S. Food and Drug Administration


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Generic Names
  • SDA
  • Sulfadiazene
  • Sulfadiazin
  • Sulfanilamidopyrimidine
  • Sulfapirimidin
  • Sulfapyrimidin
  • Sulfapyrimidine
  • Sulphadiazine
Trade Names
  • Adiazin
  • Adiazine
  • Coco-Diazine
  • Cocodiazine
  • Codiazine
  • Cremodiazine
  • Cremotres
  • Debenal
  • Deltazina
  • Diazin
  • Diazolone
  • Diazovit
  • Diazyl
  • Eskadiazine
  • Honey Diazine
  • Lantrisul
  • Lipo-Diazine
  • Lipo-Levazine
  • Liquadiazine
  • Metha-Meridiazine
  • Microsulfon
  • Neazine
  • Neotrizine
  • Palatrize
  • Pecta-Diazine
  • Piridisir
  • Pirimal
  • Pyrimal
  • Quadetts
  • Quadramoid
  • Sanodiazine
  • Spofadrizine
  • Sterazine
  • Sulfa-Triple #2
  • Sulfacombin
  • Sulfaloid
  • Sulfatryl
  • Sulfazine
  • Sulfolex
  • Sulfonamides Duplex
  • Sulfonsol
  • Sulfose
  • Terfonyl
  • Theradiazine
  • Tri-Sulfameth
  • Trifonamide
  • Triple Sulfa
  • Triple Sulfas
  • Triple Sulfoid
  • Trisem
  • Truozine
Brand Mixture Names

PharmGKB Accession Id

PA451539

Type(s):

Drug

Description

One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.

Source: Drug Bank

Indication

For the treatment of rheumatic fever and meningococcal meningitis

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Sulfadiazine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. This enzyme is needed for the proper processing of para-aminobenzoic acid (PABA) which is essential for folic acid synthesis. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.

Source: Drug Bank

Pharmacology

Sulfadiazine is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Toxicity

Oral LD 50 in mouse is 1500 mg/kg.

Source: Drug Bank

Route of Elimination

Sulfadiazine is excreted largely in the urine.

Source: Drug Bank

Chemical Properties

Chemical Formula

C10H10N4O2S

Source: Drug Bank

Isomeric SMILES

c1cnc(nc1)NS(=O)(=O)c2ccc(cc2)N

Source: OpenEye

Canonical SMILES

NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1

Source: Drug Bank

Average Molecular Weight

250.277

Source: Drug Bank

Monoisotopic Molecular Weight

250.052446274

Source: Drug Bank

SMILES

NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1

Source: Drug Bank

InChI String

InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

EvidenceGene
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
G6PD
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
UGT1A1

Drug Interactions

Interaction Description
chlorpropamide - sulfadiazine Sulfonamide/sulfonylurea: possible hypoglycemia (source: Drug Bank )
chlorpropamide - sulfadiazine Sulfonamide/sulfonylurea: possible hypoglycemia (source: Drug Bank )
cyclosporine - sulfadiazine The sulfonamide decreases the effect of cyclosporine (source: Drug Bank )
cyclosporine - sulfadiazine The sulfonamide decreases the effect of cyclosporine (source: Drug Bank )
fosphenytoin - sulfadiazine The sulfonamide increases the effect of hydantoin (source: Drug Bank )
methotrexate - sulfadiazine The sulfamide increases the toxicity of methotrexate (source: Drug Bank )
methotrexate - sulfadiazine The sulfamide increases the toxicity of methotrexate (source: Drug Bank )
phenytoin - sulfadiazine The sulfonamide increases the effect of hydantoin (source: Drug Bank )
phenytoin - sulfadiazine The sulfonamide increases the effect of hydantoin (source: Drug Bank )
tamoxifen - sulfadiazine Sulfadiazine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sulfadiazine is initiated, discontinued or dose changed. (source: Drug Bank )
tamoxifen - sulfadiazine Sulfadiazine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sulfadiazine is initiated, discontinued or dose changed. (source: Drug Bank )
tolbutamide - sulfadiazine Tolbutamide and Sulfadiazine are strong CYP2C9 inhibitors and substrates. Decreased metabolism and clearance of both agents may occur during concomitant therapy. Consider alternate therpy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose(s) changed. (source: Drug Bank )
tolbutamide - sulfadiazine Tolbutamide and Sulfadiazine are strong CYP2C9 inhibitors and substrates. Decreased metabolism and clearance of both agents may occur during concomitant therapy. Consider alternate therpy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose(s) changed. (source: Drug Bank )
torasemide - sulfadiazine Sulfadiazine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Sulfadiazine is initiated, discontinued or dose changed. (source: Drug Bank )
trimethoprim - sulfadiazine The strong CYP2C9 inhibitor, Sulfadiazine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sulfadiazine is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - sulfadiazine Sulfadiazine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if sulfadiazine is initiated, discontinued or dose changed. (source: Drug Bank )
zafirlukast - sulfadiazine Sulfadiazine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if sulfadiazine is initiated, discontinued or dose changed. (source: Drug Bank )

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
May Prevent
Contraindicated With

Publications related to sulfadiazine: 4

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. British journal of haematology. 2014. Luzzatto Lucio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug safety : an international journal of medical toxicology and drug experience. 2010. Youngster Ilan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008. Cappellini M D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
G6PD deficiency. Blood. 1994. Beutler E. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0185-0757-10
DrugBank:
DB00359
ChEBI:
9328
KEGG Compound:
C07658
KEGG Drug:
D00587
PubChem Compound:
5215
PubChem Substance:
46506164
9860
ChemSpider:
5026
Therapeutic Targets Database:
DAP001238
FDA Drug Label at DailyMed:
10549cba-9c15-4d2e-a68c-5afbc178591d

Clinical Trials

These are trials that mention sulfadiazine and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.